at Nasdaq.com (Fri, 12:22PM)
Alnylam Pharmaceuticals (ALNY) now surging 37% on heavy volume following positive Phase I trial results for ALN-TTR02, a treatment for a genetic mutation of the transthyretin gene. The mutation causes a hereditary, systemic disease called ATTR, which can damage body organs and tissue such as the peripheral nerves and heart.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 12, 2015)
at Nasdaq.com (Dec 24, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs